James I Geller1, John P Perentesis1, Xiaowei Liu2, Charles G Minard3, Rachel A Kudgus4, Joel M Reid4, Elizabeth Fox5, Susan M Blaney3, Brenda J Weigel6. 1. Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH. 2. Children's Oncology Group, Monrovia, CA. 3. Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX. 4. Mayo Clinic, Rochester, MN. 5. Children's Hospital of Philadelphia, Philadelphia, PA. 6. Masonic Children's Hospital, University of Minnesota Medical Center, Minneapolis, MN.
Abstract
BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors. METHODS: Oral tivantinib capsules were administered twice daily with food, continuously in 28-day cycles. Dose levels 170, 200, and 240 mg/m2 /dose were evaluated using a rolling-six design (Part A). In Part B, subjects received tivantinib powder sprinkled on food at the recommended phase 2 dose (RP2D) from Part A. PK, CYP2C19 genotyping, and baseline tumor tissue c-Met expression were analyzed. RESULTS: Thirty-six patients were enrolled: 20 in Part A, 6 in a PK expansion cohort, and 10 in Part B. Fifteen patients had primary central nervous system tumors and 21 had solid tumors. In Part A, there were no dose-limiting toxicities. One grade 4 intracranial hemorrhage occurred in a patient with a progressive brain tumor in the expanded PK cohort (240 mg/m2 ). PK analysis showed marked interpatient variability (20-fold) in the Cmax and AUC0-8h across all dose levels. Sprinkling tivantinib powder over food did not alter exposure. Membranous and total c-Met expression was moderate (2), low (4), or not detected (26). Two patients had stable disease as the best response. CONCLUSIONS: The RP2D of tivantinib given with food in children with refractory solid tumors is 240 mg/m2 /dose. PK of tivantinib in children demonstrated high variability. Objective responses were not observed in this phase 1 trial.
BACKGROUND: The c-Met receptor tyrosine kinase is dysregulated in many pediatric cancers. Tivantinib is an oral small molecule that inhibits the c-Met receptor tyrosine kinase. A phase 1 and pharmacokinetic (PK) trial evaluating tivantinib was conducted in children with relapsed/refractory solid tumors. METHODS: Oral tivantinib capsules were administered twice daily with food, continuously in 28-day cycles. Dose levels 170, 200, and 240 mg/m2 /dose were evaluated using a rolling-six design (Part A). In Part B, subjects received tivantinib powder sprinkled on food at the recommended phase 2 dose (RP2D) from Part A. PK, CYP2C19 genotyping, and baseline tumor tissue c-Met expression were analyzed. RESULTS: Thirty-six patients were enrolled: 20 in Part A, 6 in a PK expansion cohort, and 10 in Part B. Fifteen patients had primary central nervous system tumors and 21 had solid tumors. In Part A, there were no dose-limiting toxicities. One grade 4 intracranial hemorrhage occurred in a patient with a progressive brain tumor in the expanded PK cohort (240 mg/m2 ). PK analysis showed marked interpatient variability (20-fold) in the Cmax and AUC0-8h across all dose levels. Sprinkling tivantinib powder over food did not alter exposure. Membranous and total c-Met expression was moderate (2), low (4), or not detected (26). Two patients had stable disease as the best response. CONCLUSIONS: The RP2D of tivantinib given with food in children with refractory solid tumors is 240 mg/m2 /dose. PK of tivantinib in children demonstrated high variability. Objective responses were not observed in this phase 1 trial.
Authors: Andrew J Wagner; John M Goldberg; Steven G Dubois; Edwin Choy; Lee Rosen; Alberto Pappo; James Geller; Ian Judson; David Hogg; Neil Senzer; Ian J Davis; Feng Chai; Carol Waghorne; Brian Schwartz; George D Demetri Journal: Cancer Date: 2012-05-17 Impact factor: 6.860
Authors: Timothy A Yap; David Olmos; Andre T Brunetto; Nina Tunariu; Jorge Barriuso; Ruth Riisnaes; Lorna Pope; Jeremy Clark; Andrew Futreal; Michael Germuska; David Collins; Nandita M deSouza; Martin O Leach; Ronald E Savage; Carol Waghorne; Feng Chai; Edward Garmey; Brian Schwartz; Stan B Kaye; Johann S de Bono Journal: J Clin Oncol Date: 2011-03-07 Impact factor: 44.544
Authors: Stuart A Scott; Katrin Sangkuhl; Alan R Shuldiner; Jean-Sébastien Hulot; Caroline F Thorn; Russ B Altman; Teri E Klein Journal: Pharmacogenet Genomics Date: 2012-02 Impact factor: 2.089
Authors: Yunqing Li; Bachchu Lal; Sherwin Kwon; Xing Fan; Usha Saldanha; Thomas E Reznik; Eric B Kuchner; Charles Eberhart; John Laterra; Roger Abounader Journal: Cancer Res Date: 2005-10-15 Impact factor: 12.701
Authors: Kacper Jankowski; Magda Kucia; Marcin Wysoczynski; Ryan Reca; Dongling Zhao; Ela Trzyna; John Trent; Stephen Peiper; Marek Zembala; Janina Ratajczak; Peter Houghton; Anna Janowska-Wieczorek; Mariusz Z Ratajczak Journal: Cancer Res Date: 2003-11-15 Impact factor: 12.701
Authors: Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta Journal: Lancet Oncol Date: 2012-11-20 Impact factor: 41.316
Authors: Edwin Choy; Gregory M Cote; M Dror Michaelson; Lori Wirth; Justin F Gainor; Alona Muzikansky; Lecia V Sequist; Ryan J Sullivan; Panagiotis M Fidias; Alice Shaw; Rebecca S Heist Journal: Oncologist Date: 2022-07-05 Impact factor: 5.837